Show simple item record

dc.contributor.authorOng, David S Y
dc.contributor.authorAltorf-van der Kuil, Wieke
dc.contributor.authorVlek, Anne L M
dc.contributor.authorSchouls, Leo M
dc.contributor.authorSchoffelen, Annelot F
dc.date.accessioned2020-10-04T12:11:40Z
dc.date.available2020-10-04T12:11:40Z
dc.date.issued2020-09-14
dc.identifier.issn1473-5644
dc.identifier.pmid32924918
dc.identifier.doi10.1099/jmm.0.001251
dc.identifier.urihttp://hdl.handle.net/10029/624411
dc.description.abstractIntroduction. Increased carbapenem resistance is often caused by carbapenemase production.Aim. The objective of our study was to assess which antibiotic susceptibility patterns, as tested by automated systems, are highly associated with the absence of carbapenemase production in Enterobacteriaceae isolates, and could therefore be used as a screening tool.Methodology. Routine antibiotic susceptibility testing data from 42 medical microbiology laboratories in the Netherlands in the period between January 2011 and June 2017 were obtained from the national antimicrobial resistance surveillance programme. Data on Enterobacteriaceae isolates that had an elevated minimum inhibitory concentration (MIC) for carbapenems (meropenem >0.25 mg l-1 or imipenem >1.0 mg l-1) were selected and subjected to phenotypic or genotypic carbapenemase production testing. Routinely available amoxicillin/clavulanic acid, piperacillin/tazobactam, cefuroxime and ceftriaxone/cefotaxime susceptibilities were studied in relation to carbapenemase production by calculating the negative predictive value.Results. No evidence for carbapenemase-producing Enterobacteriaceae (CPE) was found in 767 of 1007 (76 %) isolates. The negative predictive value was highest for amoxicillin/clavulanic acid (99.6 %) and piperacillin/tazobactam (98.8 %).Conclusion.Enterobacteriaceae isolates with elevated carbapenem MICs that are susceptible to amoxicillin/clavulanic acid or piperacillin/tazobactam are unlikely to be carbapenemase producers. Preselection based on this susceptibility pattern may lead to increased laboratory efficiency and reduction of costs. Whether this is also true for countries with a different distribution of CPE species and types or a higher prevalence of CPE needs to be studied.en_US
dc.language.isoenen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectEnterobacteriaceaeen_US
dc.subjectcarbapenem-resistant Enterobacteriaceaeen_US
dc.subjectcarbapenemaseen_US
dc.subjectscreeningen_US
dc.subjectsusceptibilityen_US
dc.titleRoutinely available antimicrobial susceptibility information can be used to increase the efficiency of screening for carbapenemase-producing .en_US
dc.typeArticleen_US
dc.identifier.journalJ Med Microbiol 2020; 69(10):1235-9en_US
dc.source.journaltitleJournal of medical microbiology


This item appears in the following Collection(s)

Show simple item record